Biotech Partners

Layoffs are still all over the news but we talk to people every day who are looking for talent... so let us know where your company stands! #talent #regulatoryaffairs #clinicalresearch #lifesciences #lifesciencejobs #people

The pharmaceutical sector is experiencing significant job cuts in the first half of 2024, with major companies like Bristol Myers Squibb, Bayer, and Pfizer announcing thousands of redundancies. Bristol Myers Squibb has revealed plans to cut around 2200 jobs by the end of 2025, including 860 positions in Lawrenceville, US. This restructuring initiative aims to save the company $1.5 billion annually. Read more about these developments and their impact on the industry in the full article: #biotechjobs #clinicalresearchjobs

Seattle's thriving life-sciences sector continues to grow, creating exciting opportunities for new graduates and seasoned professionals. With a significant increase in graduates and a robust job market, now is the perfect time to dive into this dynamic industry. From R&D to medtech manufacturing, Seattle offers diverse career paths supported by institutions like the University of Washington and programs from the Life Science Washington Institute. #LifeSciences #Seattle

Technologies like 3D printing and advanced coatings are transforming the medical devices industry. By cutting development timelines, innovative treatments and devices can reach patients faster. One of the most significant benefits of 3D printing is its ability to customize and quicken production ideal for tailored patient care. Companies are investing heavily in this technology, realizing its immense potential. Furthermore, the rise of patient monitoring devices and smart implants, powered by cutting-edge coatings exemplifies how these advancements are setting new standards in healthcare. #MedicalDevices #TechTrends

Are you curious about where the top pharma and biotech job opportunities are in mid-2024? Despite significant job cuts, Massachusetts remains a key hub with a high density of job listings. However, the Northeast Megalopolis, excluding Massachusetts, leads the pack with states like New Jersey, New York, and Pennsylvania offering over 60% more job openings. Discover the full report and see where your next opportunity could be! #biotechjobs #lifesciences

Exciting news in the world of medical technology! The FDA has introduced new guidelines to promote transparency for machine learning-enabled medical devices. Device developers now have a clear roadmap on what to share and how to share it, fostering better transparency practices across the industry. Stay informed about the latest developments in medical technology. Read more here: #medicaldevices #artificialintelligence

The U.S. National Cancer Institute (NCI) has launched a pioneering initiative aimed at enhancing clinical trial enrollment across the nation. Amidst a challenging staffing landscape, the NCI has introduced the Virtual Clinical Trials Office (VCTO) program, designed to integrate remote research staff who will facilitate patient screening, enrollment, and education for NCI-funded trials. This approach not only addresses current staffing shortages but also aims to broaden access to clinical trials, particularly in underserved and minority communities. Managed by the Frederick National Laboratory for Cancer Research, this pilot program will support six U.S. clinical trial centers, including NCI-designated cancer centers and members of the Community Oncology Research Program. Learn more about this initiative and its impact on advancing cancer research and patient care: https://lnkd.in/eY7FUa_B #ClinicalTrials #CancerResearch #RemoteWork #PatientCare

Despite years of effort, women remain underrepresented in medical device clinical trials. According to a review published in JAMA Internal Medicine, a significant gap still exists, especially in cardiovascular device trials, where only 29% of participants are women. The underrepresentation calls for increased awareness and initiatives to ensure gender equity in clinical trials. Read more: https://lnkd.in/eT8Ww55M #WomenInBio #ClinicalTrial #WomenInMedicine

Understanding the gap between animal studies and clinical approvals is crucial for advancing biomedical research. A recent study by scientists at the University of Zurich sheds light on this complex issue. While animal studies often show promising initial results, only a fraction of therapies progress to regulatory approval in humans. Read more about why this gap persists and the implications for drug development: https://lnkd.in/g8T6w2AE #BiomedicalResearch #DrugDevelopment #AnimalStudies #ClinicalTrials #ResearchInsights

Major biopharma companies are partnering with the Digital Medicine Society (DiMe) on the "Building the Business Case for Digital Endpoints" project. This initiative, which includes 38 organizations such as pharma companies, tech firms, institutions, and non-profits, aims to establish industry benchmarks and create resources to promote the use of digital technologies as endpoints in clinical trials. Traditional assessments often lack the objective physiological data required to demonstrate drug effects and engage appropriate patient populations. Digital endpoints offer a potential solution to these challenges. The project's focus areas include developing a value framework for digital endpoints, creating business case models, and designing forecasting calculators. These tools will help advocates of digital technologies within pharma companies to secure necessary buy-in and funding for implementing digital endpoints. Such initiatives are expected to advance the use of digital measures and enhance the quality of clinical research. Read more about the Digital Medicine Society's digital endpoints collaboration here: https://lnkd.in/gp4YP2Kt #digitalendpoints #clinicaltrials #digitalmedicine #healthtech #biopharm